|
Patient characteristics
|
Arm A (cisplatin 100 mg/m2)
|
Arm B (cisplatin 40 mg/m2)
|
p
|
|---|
|
N = 26
|
N = 24
|
|---|
|
Gender
|
|
Male
|
25 (96.2%)
|
23 (95.8%)
|
1.000
|
|
Female
|
1 (3.8%)
|
1 (4.2%)
|
|
Age (years old)
|
|
Mean (range)
|
49.2 (33–63)
|
49.0 (32–65)
|
0.941
|
|
pT
|
|
pT1/2
|
14 (53.8%)
|
11 (45.8%)
|
0.778
|
|
pT3/4
|
12 (46.2%)
|
13 (54.2%)
|
|
pN
|
|
pN0
|
0 (0%)
|
2 (8.3%)
| |
|
pN1
|
5 (19.2%)
|
8 (33.3%)
| |
|
pN2
|
21 (80.8%)
|
14 (58.3%)
| |
|
Stage
|
|
Stage II
|
0 (0%)
|
1 (4.2%)
| |
|
Stage III
|
3 (11.5%)
|
4 (16.7%)
| |
|
Stage IV
|
23 (88.5%)
|
19 (79.2%)
| |
|
Differentiation
|
|
Well
|
7 (26.9%)
|
5 (20.8%)
| |
|
Moderate
|
15 (57.7%)
|
17 (70.8%)
| |
|
Poor
|
4 (15.4%)
|
2 (8.3%)
| |
|
Primary Site
|
|
Buccal
|
10 (38.5%)
|
9 (37.5%)
| |
|
Tongue
|
10 (38.5%)
|
11 (45.8%)
| |
|
Gum
|
5 (19.2%)
|
3 (12.5%)
| |
|
Others
|
1 (3.8%)
|
1 (4.2%)
| |
|
ECS
|
|
No
|
5 (19.2%)
|
9 (37.5%)
|
0.211
|
|
Yes
|
21 (80.8%)
|
15 (62.5%)
|
|
Margin
|
|
Negative
|
25 (96.2%)
|
20 (83.3%)
|
0.182
|
|
Positive
|
1 (3.8%)
|
4 (16.7%)
|
|
Tumor size (mm)
|
|
Mean (range)
|
31.19 (12–68)
|
34.13 (12–60)
|
0.414
|
- Abbreviations: ECS = extracapsular spreading.
